News & Views
News & Views
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
Iksuda to present growing ADC pipeline at AACR
Introduces the ProAlk payload series to address the growing challenge of ADC sequencing
Iksuda abstracts at AACR 2025
Iksuda’s abstracts have been scheduled for presentation in a Poster Session at the AACR Annual Meeting 2025 in Chicago, on Monday April 28 and have been published to the AACR Online Program Planner.
Iksuda deepens clinical pipeline
Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences
Licensing agreement with LegoChem Biosciences
LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program
LCB and Iksuda Enter into a Multi-Target Research Collaboration
LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression
IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer